Ortho Clinical Diagnostics Sustainability Profile
Ortho Clinical Diagnostics, a leading player in the in vitro diagnostics industry, is headquartered in the United States. Founded in 1939, the company has established itself as a pioneer in blood testing and transfusion diagnostics, serving healthcare providers across the globe. With a strong presence in North America, Europe, and Asia, Ortho Clinical Diagnostics focuses on delivering innovative solutions that enhance laboratory efficiency and patient care. The company’s core offerings include advanced blood screening, clinical chemistry, and immunoassay systems, distinguished by their accuracy and reliability. Notable achievements include the development of the first FDA-approved blood screening test for HIV. With a commitment to quality and innovation, Ortho Clinical Diagnostics continues to solidify its market position as a trusted partner in the healthcare sector, driving advancements in diagnostic technology.
DitchCarbon Score
How does Ortho Clinical Diagnostics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ortho Clinical Diagnostics's score of 33 is higher than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ortho Clinical Diagnostics's reported carbon emissions
In 2022, Ortho Clinical Diagnostics reported total carbon emissions of approximately 26,371,000 kg CO2e for Scope 1 and about 28,869,000 kg CO2e for Scope 2, resulting in a combined total of around 55,240,000 kg CO2e. This data is cascaded from its parent company, QuidelOrtho Corporation, reflecting the organisation's commitment to transparency in its environmental impact. Ortho Clinical Diagnostics has set ambitious climate commitments, aiming to reduce its Scope 1 and 2 emissions to near zero by 2025. Additionally, the company plans to achieve a 30% reduction in Scope 1 GHG emissions from 2022 levels by 2030, alongside a similar target for Scope 2 emissions. These initiatives demonstrate a proactive approach to addressing climate change and align with industry standards for sustainability. The organisation has not disclosed any Scope 3 emissions data, indicating a focus on direct and indirect emissions from its operations and energy use. As a current subsidiary of Ortho-Clinical Diagnostics, Inc., the company is part of a broader corporate family that prioritises sustainability and climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 19,409,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 26,398,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
How Carbon Intensive is Ortho Clinical Diagnostics's Industry?
How Carbon Intensive is Ortho Clinical Diagnostics's Location?
Ortho Clinical Diagnostics's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Ortho Clinical Diagnostics has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
